ArticleACS omega2018
Accurate Monitoring of Renal Injury State through in Vivo Magnetic Resonance Imaging with Ferric Coordination Polymer Nanodots.
Article in ACS omega, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
- The Renal Clearable Magnetic Resonance Imaging Contrast Agents: State of the Art and Recent Advances.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is highly challenging to detect the pathophysiology of the diseased kidneys and achieve precise diagnosis because there are few in vivo noninvasive imaging techniques to quantitatively assess kidney dysfunction. This longstanding challenge is normally attributed to the limited molecular contrast agents which can be addressed with renal clearable nanoprobes. In this report, we demonstrate the use of magnetic resonance imaging along with renal clearable ferric coordination polymer nanodots (Fe-CPNDs) for in vivo monitoring the kidney dysfunction effects following drug (daunomycin)-induced kidney injury. After intravenous injection of Fe-CPNDs, the change of the MR signal in the kidney can be precisely correlated with local pathological lesion which is demonstrated by renal anatomic details and biochemical examinations of urine and blood. This finding opens the door to the possibility of noninvasively assessing kidney dysfunction and local injuries.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.